THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION.
PUBLICATION RELATING TO A TRANSPARENCY NOTIFICATION (ARTICLE 14, 1ST PARAGRAPH, OF THE LAW OF |
Acacia Pharma
1. Summary of the notification
2. Content of notification
The notification dated
- Reason of the notification – acquisition or disposal of voting securities or tights
- Notification by – a parent undertaking or a controlling person
- Persons subject to the notification requirement:
Address (for legal entities) | |
250 W 55th St 16C | |
- Date on which the threshold is crossed –
25 June 2021 - Threshold that is crossed – 5%
- Denominator – 93,713,951
- Notified details:
A) Voting rights | Previous notification | After the transaction | |||
# of voting rights | # of voting rights | % of voting rights | |||
Holders of voting rights | Linked to securities | Not linked to securities | Linked to securities | Not linked to securities | |
0 | 0 | 0.00% | 0.00% | ||
4,931,684 | 4,844,404 | 0 | 4.86% | 0.00% | |
Subtotal | 4,844,404 | 4.86% | |||
TOTAL | 4,844,404 | 0 | 4.86% | 0.00% |
B) Equivalent financial instruments | After the transaction | |||||
Holders of equivalent financial instruments | Type of financial instrument | Expiration date | Exercise period or date | # of voting rights that may be acquired if the instrument is exercised | % of voting rights | Settlement |
TOTAL | 0 | 0.00% | ||||
TOTAL (A+B) | # of voting rights | % of voting rights | ||||
CALCULATE | 4,844,404 | 4.86% |
Full chain of controlled undertakings through which the holding is effectively held:
Coltrane Asset Management, L.P. is an investment advisor which manages funds and accounts which hold the shares reported in this filing.Coltrane Asset Management, L.P. can exercise the voting rights at its discretion, without any instruction from its clients.Coltrane Asset Management, L.P. is controlled byColtrane Asset Management Holdings, Ltd , which is controlled byMandeep Manku .
3. Miscellaneous
- This press release is available on
Acacia Pharma Group plc’s website (https://acaciapharma.com/investors/regulatory-announcements) - The notification may be found on
Acacia Pharma Group plc’s website ((https://acaciapharma.com/investors/regulatory-announcements)
Contacts
+44 1223 919760 / +1 317 505 1280 IR@acaciapharma.com | International Media +44 20 7638 9571 acaciapharma@medistrava.com |
US Investors +1 917-734-7387 ikoffler@lifesciadvisors.com | Media in +32 499 58 55 31 chrisvanraemdonck@telenet.be |
The Officers’ Mess,
Company number 9759376
About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy. The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address.
Acacia Pharma's first product, BARHEMSYS® (amisulpride injection) is marketed in the US for the management of postoperative nausea & vomiting (PONV).
BYFAVO™ (remimazolam) for injection, a very rapid onset/offset IV benzodiazepine sedative is approved and launched in the US for use during invasive medical procedures in adults lasting 30 minutes or less, such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from
APD403 (intravenous and oral amisulpride), a selective dopamine antagonist for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.
Acacia Pharma has its US headquarters in
www.acaciapharma.com
© OMX, source